Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers

Venus Remedies CMP Rs 1,572 (16 Oct 2026). Market cap Rs 2,091 Cr. ROE 15.49%. P/E 18.00x versus Industry P/E 36.42x.

Is Venus Remedies the best stock in its sector? The stock trades on the NSE at Rs 1,572 as of 16 October 2026, within its 52-week range of Rs 432.10 to Rs 2,044.30. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Venus Remedies

Venus Remedies Ltd is a Panchkula based pharmaceutical company that focuses on injectable medicines. Its range includes antibiotics, oncology and critical care injectables, which it sells in India and in many overseas markets. At a market capitalisation of Rs 2,091 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.

Is Venus Remedies the Best Stock in Its Sector?

Venus Remedies makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Venus Remedies’ 18.00x P/E is below the 36.42x Industry P/E, Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x, while its 15.49% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.02 is below Marksans Pharma at 0.11 and Ajanta Pharma at 0.06.

Metric	Venus Remedies
CMP (NSE)	Rs 1,572.20
52-Week High / Low	Rs 2,044.30 / Rs 432.10
Market Cap	Rs 2,091 Cr
P/E (TTM) vs Industry P/E	18.00x vs 36.42x
P/B	3.15
ROE	15.49%
EPS (TTM)	Rs 86.92
Dividend Yield	0.64%
Debt to Equity	0.02

Compare Venus Remedies Against Other Pharmaceuticals Sector Stocks

How Venus Remedies Compares Against Its Pharmaceuticals Sector Peers

The table below sets Venus Remedies against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Venus Remedies	2,091	18.00	15.49%	0.02
Marksans Pharma	14,236	27.32	13.82%	0.11
Ajanta Pharma	41,211	36.31	23.33%	0.06
Peer average (2 companies)	–	31.82	18.57%	0.08

Measured against the peer averages, Venus Remedies’ P/E is 43 percent below the 31.82x average, and its ROE is 3.08 percentage points below the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Venus Remedies Worth Watching in Pharmaceuticals

• Scale: At Rs 2,091 Cr, its market capitalisation is smaller than Marksans Pharma (Rs 14,236 Cr) and Ajanta Pharma (Rs 41,211 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Regulated market approvals, export orders for injectables and hospital demand for antibiotics and critical care drugs shape its sales.
• Key risk: The share has risen to about three and a half times its 52-week low, so expectations are high, and a small cap pharma name can be volatile.

Venus Remedies Valuation: Is It Justified?

At a P/B ratio of 3.15, the market pays about Rs 3.15 for every rupee of book value, and the EPS (TTM) of Rs 86.92 is the earnings base behind the P/E. The stock trades about 23 percent below its 52-week high and about 3.6 times its 52-week low. The dividend yield of 0.64% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Venus Remedies and other Pharmaceuticals sector stocks.

How to Track Venus Remedies Before You Invest

Before deciding whether Venus Remedies deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.

1. Open the Univest Screener and search for Venus Remedies to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Venus Remedies gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Venus Remedies the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Venus Remedies has a 15.49% ROE and trades at 18.00x P/E against a 36.42x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 18.57% peer average and its P/E is below the 31.82x peer average. Its debt to equity ratio of 0.02 is below the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Venus Remedies?

Ans. Venus Remedies was trading at Rs 1,572.20 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 432.10 to Rs 2,044.30. That leaves the share price 23 percent short of the 52-week high and 3.6 times the 52-week low. Its market capitalisation is Rs 2,091 Cr and its EPS (TTM) is Rs 86.92, which is the earnings figure behind the 18.00x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Venus Remedies belong to?

Ans. Venus Remedies is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P/E used in this article. The 2 named peers compared here are Marksans Pharma and Ajanta Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Venus Remedies compare to its sector peers on P/E?

Ans. Venus Remedies’ P/E of 18.00x is below the 31.82x average of the 2 named peers, with Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x. It also sits below the 36.42x Industry P/E, which is the benchmark for the wider Pharmaceuticals sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 3.15 gives one more view of how the market values its book value.

What is Venus Remedies’ return on equity?

Ans. Venus Remedies reported a return on equity of 15.49%, which is below the 18.57% average of its named peers, with Marksans Pharma at 13.82% and Ajanta Pharma at 23.33%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.02 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Venus Remedies based on its sector position?

Ans. Sector position is only one input into an investment decision. Venus Remedies has a 15.49% ROE and a 18.00x P/E, which make it worth researching further, and its dividend yield is 0.64%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.